Bayer's Recovery Faces Its Sternest Test: A September Court Date That Could Make or Break the Comeback
Published on 08/13/2026 at 08:21 | Redaktion boerse-global.de
The stock has climbed 79 percent over the past twelve months and sits 87 percent above its November trough, yet the narrative driving Bayer's resurgence is no longer purely about the numbers. When the shares slipped 2.1 percent on Wednesday to close at EUR 48.14, the dip landed on a day when two banks delivered sharply divergent verdicts on the company's prospects — a split that underscores just how much hangs on a single hearing scheduled for September 14.
That date marks the latest — and possibly decisive — attempt to secure court approval for the USD 7.25 billion Roundup settlement. The hearing, which has already been postponed multiple times, was pushed back again at the joint request of Bayer, its Monsanto subsidiary, and the plaintiffs' attorneys in Missouri. Until it takes place, the legal overhang will continue to shadow every piece of good news the company produces.
A Rally Built on Solid Fundamentals
The recent run-up traces back to the second-quarter report released on August 5, which delivered a genuine surprise. Adjusted EBITDA came in at EUR 2.14 billion, up 1.9 percent year-on-year, while group revenue reached EUR 10.74 billion. Adjusted earnings per share beat market expectations, and although first-half revenue slipped slightly, net income improved and management reaffirmed its full-year guidance.
The standout performer was the agriculture division, which exceeded expectations that had been deliberately tempered in advance. Bayer's India subsidiary also contributed a stronger quarterly profit, helped by falling costs. These operational improvements formed the bedrock for a wave of price-target upgrades in early August, with the DZ Bank leading the charge on August 4 by lifting its fair value from EUR 54 to EUR 60 and reiterating a "Buy" rating, citing operational stabilization, debt reduction progress, and advances on US legal risks.
Should investors sell immediately? Or is it worth buying Bayer?
UBS and Deutsche Bank Research followed suit, raising their targets to EUR 60 and EUR 62 respectively, both maintaining buy recommendations. Jefferies, however, struck a more cautious tone, keeping its "Hold" rating with a target of EUR 46 — a level that sits below the current share price.
The Numbers Behind the Divergence
That gap in analyst opinion — a 16-euro spread between the highest and lowest targets — reflects two fundamentally different readings of the same situation. The optimists point to a company that described itself as "operational on track," with momentum in cost reduction and a stabilizing core business. The skeptics see a stock trading roughly 20 percent above its 200-day moving average, with unresolved litigation that could still deliver an adverse outcome.
At EUR 48.14, the shares sit about 11 percent below the 52-week high of EUR 53.86 reached in early July, yet maintain a nearly 7 percent premium to the 50-day average — evidence that the medium-term uptrend remains intact even as the recent pullback suggests resistance at current levels. The stock has given back roughly 2.5 percent since the earnings-driven surge, and the relative strength index at 52.7 points to a consolidation phase rather than a decisive breakout in either direction.
Annualized volatility of 26 percent tells its own story: this is a stock that rewards patience but punishes complacency. With a market capitalization of EUR 48.36 billion, Bayer remains a substantial presence in European equities, but the legal uncertainty has kept a lid on how far the re-rating can go.
All Eyes on September
The coming weeks are likely to be defined by anticipation rather than action. A favorable outcome at the September hearing could serve as the catalyst for a further re-rating, potentially narrowing the gap between the current price and the more ambitious analyst targets. Conversely, fresh delays or complications would weigh on the recovery narrative that has driven the stock's impressive run.
For now, the 46-to-60-euro range of analyst targets encapsulates the entire debate: those who believe the operational turnaround is real and sustainable, and those who cannot look past the legal sword of Damocles hanging over the company. The September 14 hearing may well determine which camp ultimately proves correct — and whether Bayer's recovery story has further to run or has already priced in its best days.
Ad
Bayer Stock: New Analysis - 13 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
